Pathology Company Healius Faces Financial Struggles

  • 📰 FinancialReview
  • ⏱ Reading Time:
  • 30 sec. here
  • 8 min. at publisher
  • 📊 Quality Score:
  • News: 36%
  • Publisher: 90%

Healthcare ニュース

Pathology,Healius,Australia

Healius, a pathology company in Australia, is experiencing a decline in its sharemarket capitalisation and had to undergo an emergency capital raising. The chairwoman resigned before facing a potential vote for re-election.

A visit to the doctor regularly involves the GP needing a blood sample. The patient is sent to a collection centre where a kindly nurse extracts blood from a vein, packages up the test tubes for transportation to a pathology lab for examination, with results returned to the GP for a follow-up appointment. The ageing population and strong migration levels of up to 500,000 new arrivals annually mean pathology companies are seemingly in a sweet spot for demand for their services.

in Australia’s pathology sector, is battling a fall from grace which has stripped $2 billion from its sharemarket capitalisation in two years. It was forced by its banks into an emergency capital raising of $187 million at $1.20 a share on November 20. The heavily discounted rights issue triggered a rapid boardroom overhaul as chairwomanHealius CEO Maxine Jaquet at the annual meeting on November 28.Ms Macdonald, chairwoman since October 2022, jumped before she was pushed. Proxies showed she would have lost a vote for her re-election at the annual meeting on November 2

このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む:

 /  🏆 2. in JP
 

コメントありがとうございます。コメントは審査後に公開されます。

日本 最新ニュース, 日本 見出し